| Grant ID | RP200655 |
| Awarded On | August 19, 2020 |
| Title | A Novel Organoid Platform to Modulate Human Neural Networks Integrated with Glioblastoma Stem Cells |
| Program | Academic Research |
| Award Mechanism | High Impact/High Risk |
| Institution/Organization | The Methodist Hospital Research Institute |
| Principal Investigator/Program Director | Robert Krencik |
| Cancer Sites | Brain and Other Nervous System |
| Contracted Amount | $249,372 |
| Lay Summary |
Our goal is to establish a new and well-defined experimental human-derived cellular tool that can serve as a drug testing platform for brain cancers, including glioblastoma. This tool will consist of patient-derived glioblastoma stem cells systematically incorporated within human neural cells that are rapidly derived from pluripotent stem cells. We will also incorporate a method to pace neural activity within the platform which will enable modeling of human brain activity. The significance of this project is that it is expected to provide a new drug testing platform that is a better recapitulation of the brain environment as compared to existing technologies and, thus, it will accelerate the... |